Nektar Therapeutics’ NKTR-181 Is Expected to Be Key Growth Driver

On June 14, 2018, Nektar Therapeutics announced new study data for its opioid therapy drug NKTR-181 at the 80th Annual Scientific Meeting of the CPPD (College on Problems of Drug Dependence) in San Diego, California. Nektar Therapeutics’ NKTR-181 is a NME (new molecular entity) and the first analgesic opioid molecule to exhibit a reduced incidence of specific CNS-mediated side effects such as euphoria through the targeted alteration of brain-entry kinetics. According to Steve Doberstein, the senior vice president and chief research and development officer of Nektar, “We are privileged that these meaningful new data from our clinical trials, as well as our translational research, were recognized for oral presentation at the prestigious CPDD meeting.